title: [Diuretics in the neonatal period].
abstract: Careful management of fluid and electrolytes may require the rational use of diuretic agents in some neonatal pathological conditions. High efficacy diuretics include "loop" diuretics--furosemide, bumetanide and ethacrynic acid. The elimination half-life and renal effects of furosemide are prolonged in newborn infants as compared with adults. In congestive heart failure, the mean net losses associated with a 1 mg i.v. dose of furosemide, are 28 ml/kg, 3.6 mmol/kg and 0.3 mmol/kg respectively for water, sodium and potassium. The furosemide--dopamine (2 micrograms/kg/min) combination may improve renal insufficiency in the course of respiratory distress syndrome (RDS). Furosemide also decreases the deleterious renal effects of indomethacin. Beneficial effect of furosemide has not been clearly demonstrated in RDS and bronchopulmonary dysplasia (BPD). Metabolic alkalosis, hypokalemia, renal calcifications, cholelithiasis and worsening in BPD outcome have been related to long-term administrations of furosemide. The risk of furosemide induced-ototoxicity has not been clearly assessed in newborn infants. Medium efficacy diuretics (thiazides) act primarily in the early distal tubule. Chlorothiazide may reduce calcium urinary excretion in neonates receiving long-term furosemide therapy. Weak diuretics (potassium-sparing diuretics and carbonic anhydrase inhibitors) cause excretion of less than 5% of the filtered sodium. Potassium-sparing diuretics are usually reserved for neonates with congestive heart failure and are always used in combination.
authors.affiliation: Service de pédiatrie, CHUV, Lausanne, Suisse.
authors.forename: J P
authors.initials: JP
authors.lastname: Guignard
authors.forename: L
authors.initials: L
authors.lastname: Dubourg
authors.forename: J B
authors.initials: JB
authors.lastname: Gouyon
mesh_terms: D001581:Benzothiadiazines; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy / Q000503:physiopathology; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use*; D005665:Furosemide / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D007234:Infant, Premature; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000503:physiopathology; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology; D014882:Water-Electrolyte Balance / Q000502:physiology
chemical_list: D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D005665:Furosemide
vernacular_title: Les diurétiques en période néonatale.